Rapid Automated Immunoassay for HTLV I/II Antibodies Now Available
|
By LabMedica International staff writers Posted on 05 Aug 2015 |
|
Image: The Elecsys benchtop analyzer was designed for small to medium workloads (Photo courtesy of Roche).
An automated immunoassay for the detection of antibodies against human T-lymphotropic virus I or II (HTLV-I/II) in donated blood and routine diagnostic samples and is now available for use by blood centers and clinical laboratories.
The Roche (Basel, Switzerland) HTLV-I/II immunoassay was designed for use on the Elecsys benchtop analyzer. This IVD instrument is powered by enhanced chemiluminescence (ECL) technology, which provides precise and reliable patient results that contribute to better patient care.
The Elecys instrument uses two electrochemically active substances, a ruthenium complex and tripropylamine (TPA). These reagents are involved in the reaction that leads to the emission of light. Ruthenium and TPA are non-isotopic and highly stable at base state. Only when voltage is applied and the labeled compound is repeatedly excited do the reactants begin emitting photons. To start the reaction, voltage is applied between the working and counter electrode, and an electrical field is created, ensuring a precisely controlled and timed reaction.
The operation is performed on a solution containing sample and reagents that are aspirated into the measuring cell. A magnetic field is applied, and the paramagnetic beads (coated with antigen/antibody complexes bound by streptavidin-biotin) are bound to the surface of the measuring cell. ProCell solution is introduced in order to separate the bound immunoassay complexes from the free remaining particles and to provide TPA, which is essential for the ECL-reaction. The test procedure requires about 18 minutes to run a single test.
“Globally there are around 20 million people infected with HTLV-I/II, many of whom are unknown carriers. If the virus is undetected in donors, the risk of spreading the infection increases,” said Roland Diggelmann, COO of the Roche Diagnostics Division. “Roche is uniquely positioned to help blood centers improve their testing efficiency, based on our broad assay portfolio and integrated molecular and serology laboratory solutions.”
Related Links:
Roche
The Roche (Basel, Switzerland) HTLV-I/II immunoassay was designed for use on the Elecsys benchtop analyzer. This IVD instrument is powered by enhanced chemiluminescence (ECL) technology, which provides precise and reliable patient results that contribute to better patient care.
The Elecys instrument uses two electrochemically active substances, a ruthenium complex and tripropylamine (TPA). These reagents are involved in the reaction that leads to the emission of light. Ruthenium and TPA are non-isotopic and highly stable at base state. Only when voltage is applied and the labeled compound is repeatedly excited do the reactants begin emitting photons. To start the reaction, voltage is applied between the working and counter electrode, and an electrical field is created, ensuring a precisely controlled and timed reaction.
The operation is performed on a solution containing sample and reagents that are aspirated into the measuring cell. A magnetic field is applied, and the paramagnetic beads (coated with antigen/antibody complexes bound by streptavidin-biotin) are bound to the surface of the measuring cell. ProCell solution is introduced in order to separate the bound immunoassay complexes from the free remaining particles and to provide TPA, which is essential for the ECL-reaction. The test procedure requires about 18 minutes to run a single test.
“Globally there are around 20 million people infected with HTLV-I/II, many of whom are unknown carriers. If the virus is undetected in donors, the risk of spreading the infection increases,” said Roland Diggelmann, COO of the Roche Diagnostics Division. “Roche is uniquely positioned to help blood centers improve their testing efficiency, based on our broad assay portfolio and integrated molecular and serology laboratory solutions.”
Related Links:
Roche
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Gel Cards
DG Gel Cards
Hemodynamic System Monitor
OptoMonitor
Latest Hematology News
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
- WBC Count Could Predict Severity of COVID-19 Symptoms
- New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
- Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
- POC Hemostasis System Could Help Prevent Maternal Deaths
Channels
Clinical Chemistry
view channel
Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
Multiple myeloma is an incurable cancer of the bone marrow, and while many patients now live for more than a decade after diagnosis, a significant proportion relapse much earlier with poor outcomes.... Read more
Compact Raman Imaging System Detects Subtle Tumor Signals
Accurate cancer diagnosis often depends on labor-intensive tissue staining and expert pathological review, which can delay results and limit access to rapid screening. These conventional methods also make... Read more
Molecular Diagnostics
view channel
Blood Test Combined with MRI Brain Scans Reveals Two Distinct Multiple Sclerosis Types
Multiple sclerosis (MS) affects more than 2.8 million people worldwide, yet predicting how the disease will progress in individual patients remains difficult. Current MS classifications are based on clinical... Read more
Ultra-Sensitive Blood Biomarkers Enable Population-Scale Insights into Alzheimer’s Pathology
Accurately estimating how many people carry Alzheimer’s disease pathology has long been a challenge, as traditional methods rely on small, clinic-based samples rather than the general population.... Read more
Blood Test Could Predict Death Risk in World’s Most Common Inherited Heart Disease
Hypertrophic cardiomyopathy (HCM) is the world’s most common inherited heart condition and affects millions of people globally. While some patients live with few or no symptoms, others develop heart failure,... Read more
Hematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
Colon cancer remains a major cause of cancer-related illness, with many patients facing relapse even after surgery and chemotherapy. Up to 40% of people with stage III disease experience recurrence, highlighting... Read more
Microbiology
view channel
New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
Urinary tract infections affect around 152 million people every year, making them one of the most common bacterial infections worldwide. In routine medical practice, diagnosis often relies on rapid urine... Read more
Breakthroughs in Microbial Analysis to Enhance Disease Prediction
Microorganisms shape human health, ecosystems, and the planet’s climate, yet identifying them and understanding how they are related remains a major scientific challenge. Even with modern DNA sequencing,... Read more
Pathology
view channel
Genetics and AI Improve Diagnosis of Aortic Stenosis
Aortic stenosis is a progressive narrowing of the aortic valve that restricts blood flow from the heart and can be fatal if left untreated. There are currently no medical therapies that can prevent or... Read more
AI Tool Simultaneously Identifies Genetic Mutations and Disease Type
Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer
Head and neck cancers are among the most aggressive malignancies worldwide, with nearly 900,000 new cases diagnosed each year. Monitoring these cancers for recurrence or relapse typically relies on tissue... Read moreIndustry
view channel
BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) has entered into a strategic collaboration with the Institute for Immunology and Immune Health (I3H, Philadelphia, PA, USA) at the University... Read more
